Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Eqtec agrees amendment to Verde subscription

(Sharecast News) - Waste-to-energy technology developer Eqtec updated the market on the Verde Corporation subscription on Friday, confirming that an amendment to the subscription letter had been agreed upon with Verde. The AIM-traded firm said the amendment allowed for the proceeds of the subscription to be received by Eqtec on or before 16 May.

Eqtec also highlighted the continuation of the agreement for the conversion of debt into equity by significant shareholders Pitcole and Altair Group Investment.

Moreover, the undertaking by YA-RF lenders not to convert the remaining £0.6m syndicated facility until after 30 June remained intact.

Eqtec also reaffirmed the availability of its £3m syndicated funding facility, initially announced on 20 November last year.

Currently, £0.95m had been drawn from the facility, leaving £2.05m undrawn, ensuring financial stability and support for Eqtec's operations.

At 1046 BST, Eqtec shares were down 2.44% at 1.9p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

Hikma boosts injectables business with Xellia assets acquisition
(Sharecast News) - Hikma Pharmaceuticals said on Monday that it has agreed to buy parts of Xellia Pharmaceuticals, a Copenhagen-based specialty company focusing on providing anti-infective treatments and other critical care therapies, for up to $185m.
Ascential on track to hit targets this year
(Sharecast News) - Publishing, events and B2B consultancy group Ascential has said that trading is in line with expectations for the full year, helped by strong growth in marketing and fintech operations.
AstraZeneca's Imfinzi gets US approval for endometrial cancer patients
(Sharecast News) - AstraZeneca said its Imfinzi cancer treatment had been approved in the US as treatment for adult patients with primary advanced or recurrent endometrial cancer.
British Land CFO to join Kingfisher
(Sharecast News) - B&Q owner Kingfisher said it had appointed British Land chief financial officer Bhavesh Mistry to the same role at the home improvement company.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.